• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    IQVIA Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

    4/24/25 5:05:07 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $IQV alert in real time by email
    8-K
    false 0001478242 --12-31 0001478242 2025-04-24 2025-04-24
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): April 24, 2025

     

     

    IQVIA HOLDINGS INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-35907   27-1341991

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

    2400 Ellis Road

    Durham, North Carolina 27703

    (Address of principal executive offices)

    Registrant’s telephone number, including area code: (919) 998-2000

    Not Applicable

    (Former name or former address, if changed since last report.)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class

     

    Trading

    Symbol

     

    Name of Each Exchange

    on which Registered

    Common Stock, par value $0.01 per share   “IQV”   New York Stock Exchange LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.03

    Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

    On April 24, 2025, IQVIA Holdings Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders. Among other matters, stockholders approved a proposal to amend the Company’s Amended and Restated Certificate of Incorporation (the “Charter”) to provide for the exculpation from liability for certain officers of the Company to the fullest extent permitted by Delaware law and to remove obsolete provisions relating to the Company’s previous classified board structure. The amendment to the Charter was previously approved by the Company’s board of directors, subject to stockholder approval. The amendment to the Charter became effective upon the filing of an Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on April 24, 2025.

    The foregoing description of the amendment to the Charter is not complete and is qualified in its entirety by reference to the Amended and Restated Certificate of Incorporation effective as of April 24, 2025, which is filed as Exhibit 3.1 hereto and incorporated herein by reference.

     

    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    As discussed under Item 5.03 of this Current Report on Form 8-K, on April 24, 2025, the Company held its 2025 Annual Meeting of Stockholders. As of February 24, 2025, the record date for the meeting, there were 176,315,036 shares of the Company’s common stock outstanding and entitled to vote on all matters. At the meeting, stockholders voted on the following proposals:

    Proposal No. 1 – The following nominees were elected by majority vote to serve on the Company’s board of directors for one-year terms based upon the following votes:

     

         For      Against      Abstain      Broker Non-Votes  

    Ari Bousbib

         144,332,933        7,497,655        559,543        8,003,968  

    Carol J. Burt

         143,757,830        8,529,707        102,595        8,003,967  

    John G. Danhakl

         148,121,196        4,095,102        173,834        8,003,967  

    James A. Fasano

         150,129,399        2,157,255        103,478        8,003,967  

    Colleen A. Goggins

         145,749,266        6,537,216        103,649        8,003,968  

    John. M. Leonard, MD

         150,069,636        2,214,918        105,578        8,003,967  

    Leslie Wims Morris

         151,220,467        994,026        175,640        8,003,966  

    Todd B. Sisitsky

         131,664,362        20,622,138        103,632        8,003,967  

    Sheila A. Stamps

         151,075,004        1,210,413        104,715        8,003,967  

    Proposal No. 2 – An advisory (non-binding) vote to approve the 2024 compensation of the Company’s named executive officers received the following votes:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    125,637,769   26,212,786   539,576   8,003,968

    Proposal No. 3 – The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025, was ratified based upon the following votes:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    145,558,841   14,744,090   91,166   — 

    Proposal No. 4 – The Company’s proposal to approve an amendment to the Charter regarding officer exculpation was approved by stockholders based upon the following votes:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    138,590,858   13,662,237   137,037   8,003,967

     


    Proposal No. 5 – An advisory (non-binding) stockholder proposal concerning special stockholder meetings received the following votes:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    66,155,724   86,013,439   220,969   8,003,967

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit
    No.
       Description
    3.1    Amended and Restated Certificate of Incorporation of IQVIA Holdings Inc., effective April 24, 2025.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Date: April 24, 2025

     

    IQVIA HOLDINGS INC.
    By:  

    /s/ Eric M. Sherbet

      Eric M. Sherbet
      Executive Vice President, General Counsel and Secretary
    Get the next $IQV alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $IQV

    DatePrice TargetRatingAnalyst
    4/25/2025$160.00Buy → Hold
    HSBC Securities
    4/10/2025$170.00Overweight → Equal Weight
    Barclays
    2/3/2025Buy → Neutral
    BTIG Research
    12/20/2024$250.00Overweight
    Stephens
    10/14/2024Buy
    Redburn Atlantic
    9/4/2024$275.00Outperform
    RBC Capital Mkts
    7/24/2024$266.00 → $242.00Buy → Hold
    Jefferies
    6/6/2024$270.00Buy
    Goldman
    More analyst ratings

    $IQV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Cherofsky Keriann sold $105,150 worth of shares (549 units at $191.53), decreasing direct ownership by 16% to 2,910 units (SEC Form 4)

      4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

      7/25/25 5:01:44 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Officer Sherbet Eric sold $1,102,290 worth of shares (5,800 units at $190.05), returned $1,153,907 worth of shares to the company (6,070 units at $190.10) and exercised 11,870 shares at a strike of $97.20 (SEC Form 4)

      4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

      7/25/25 5:00:57 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Wims Morris Leslie

      4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

      5/9/25 4:51:44 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • IQVIA downgraded by HSBC Securities with a new price target

      HSBC Securities downgraded IQVIA from Buy to Hold and set a new price target of $160.00

      4/25/25 8:30:17 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA downgraded by Barclays with a new price target

      Barclays downgraded IQVIA from Overweight to Equal Weight and set a new price target of $170.00

      4/10/25 8:49:29 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA downgraded by BTIG Research

      BTIG Research downgraded IQVIA from Buy to Neutral

      2/3/25 8:45:01 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    SEC Filings

    See more
    • SEC Form 10-Q filed by IQVIA Holdings Inc.

      10-Q - IQVIA HOLDINGS INC. (0001478242) (Filer)

      7/22/25 4:50:23 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)

      7/22/25 7:06:22 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

      8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)

      6/4/25 4:30:40 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Danhakl John G bought $255,740 worth of shares (1,275 units at $200.58) (SEC Form 4)

      4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

      2/7/25 7:03:59 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IQVIA Reports Second-Quarter 2025 Results

      Revenue of $4,017 million, up 5.3 percent year-over-year GAAP Net Income of $266 million, Adjusted EBITDA of $910 million GAAP Diluted Earnings per Share of $1.54, Adjusted Diluted Earnings per Share of $2.81 R&D Solutions quarterly bookings of $2.5 billion, representing a book-to-bill ratio of 1.12x R&D Solutions contracted backlog of $32.1 billion, up 5.1 percent year-over-year TAS Revenue of $1,628 million, up 8.9 percent year-over-year Repurchased $607 million of common stock in the quarter, over $1 billion year-to-date IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence

      7/22/25 7:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Healthcare's $110B AI Surge Is Picking Up Speed--and It's Just the Beginning

      USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- As artificial intelligence reshapes the future of medicine, understanding how patients actually feel about it is becoming just as critical as the technology itself. A new study published in Nature introduced an "AI Affinity Score" to measure patient comfort with AI in clinical settings—showing that education level and region heavily influence acceptance. The findings suggest that personalizing AI integration based on patient attitudes can enhance care quality and satisfaction. That kind of insight is already guiding investor attention toward emerging opportunities in a secto

      7/8/25 9:34:00 AM ET
      $CI
      $GEHC
      $IQV
      $WAY
      Medical Specialities
      Health Care
      Medical Electronics
      Biotechnology: Commercial Physical & Biological Resarch
    • IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025

      IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its second-quarter 2025 financial results before the market opens on Tuesday, July 22, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. T

      7/1/25 7:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Leadership Updates

    Live Leadership Updates

    See more
    • IQVIA Appoints Richard Staub III President of Research & Development Solutions

      IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has appointed Richard Staub III, currently senior advisor to the Chairman and CEO, as president of its Research & Development Solutions (R&DS) business unit. Richard is a vastly experienced executive with 34 years in the life science sector and has held numerous senior executive roles across multiple contract research organizations. Richard previously served as the president of the R&DS business unit at IQVIA from 2016 to 2022. Under his exceptional leadership the R&DS business unit accelerated its growth, recorded consec

      9/25/23 8:01:00 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA Appoints Dr. Christina Mack Chief Scientific Officer of Real World Solutions

      IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced the appointment of Dr. Christina Mack to serve as chief scientific officer for the company's Real World Solutions (RWS) business, effective July 7, 2022. Christina is succeeding Dr. Nancy Dreyer, who is retiring after nearly two decades with IQVIA. In this new role, Dr. Mack will be responsible for guiding the design and execution of innovative real-world studies, using advanced enriched evidence to enable faster decision-making and help advance clinical practices. Christina's career at IQVIA has included several leadership roles, all

      6/7/22 8:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA Appoints Costa Panagos President of Research & Development Solutions (R&DS)

      IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract services to the life sciences industry, today announced the appointment of Costa Panagos, to serve as president of its Research & Development Solutions (R&DS) business unit. He is succeeding Richard Staub III, who is retiring after a successful career spanning more than three decades. Mr. Staub will remain with the company as a senior advisor to the CEO and continue supporting business development and client management activities. Mr. Panagos has more than 25 years of industry experience serving life sciences customers and managing contract research (CRO) organizati

      3/14/22 9:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Financials

    Live finance-specific insights

    See more
    • IQVIA Reports Second-Quarter 2025 Results

      Revenue of $4,017 million, up 5.3 percent year-over-year GAAP Net Income of $266 million, Adjusted EBITDA of $910 million GAAP Diluted Earnings per Share of $1.54, Adjusted Diluted Earnings per Share of $2.81 R&D Solutions quarterly bookings of $2.5 billion, representing a book-to-bill ratio of 1.12x R&D Solutions contracted backlog of $32.1 billion, up 5.1 percent year-over-year TAS Revenue of $1,628 million, up 8.9 percent year-over-year Repurchased $607 million of common stock in the quarter, over $1 billion year-to-date IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence

      7/22/25 7:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025

      IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its second-quarter 2025 financial results before the market opens on Tuesday, July 22, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. T

      7/1/25 7:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA Reports First-Quarter 2025 Results

      Revenue of $3,829 million GAAP Net Income of $249 million, Adjusted EBITDA of $883 million GAAP Diluted Earnings per Share of $1.40, Adjusted Diluted Earnings per Share of $2.70 R&D Solutions quarterly bookings of $2.1 billion, resulting in trailing-twelve-month bookings of $9.7 billion and a trailing-twelve-month book-to-bill ratio of 1.14x R&D Solutions contracted backlog of $31.5 billion, up 4.8 percent year-over-year TAS Revenue of $1,546 million, up 6.4 percent reported year-over-year and 7.6 percent at constant currency Operating Cash Flow of $568 million and Free Cash Flow of $426 million, up 13 percent year-over-year, representing 89 percent of Adjusted Net Income Rep

      5/6/25 7:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by IQVIA Holdings Inc.

      SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)

      8/15/24 7:57:23 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G filed by IQVIA Holdings Inc.

      SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)

      2/14/24 4:11:54 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by IQVIA Holdings Inc. (Amendment)

      SC 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)

      1/25/24 4:59:33 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care